Akido Labs: Leveraging AI to Transform Healthcare Delivery and Access

From Goldman Sachs to the National Library of Medicine, Matt Rothstein's career has been defined by building systems at the intersection of technology and human outcomes. His latest venture as head of engineering at Akido Labs is no exception. Rothstein believes that regardless of domain, broken infrastructure and misaligned incentives often lead to poor experiences for those who need it most.

“Healthcare has the same problem, probably worse,” Rothstein told Fierce Healthcare. “The system was designed around institutional convenience, not patient experience.”

Akido Labs, launched in 2015, is an AI-native healthcare company that aims to combat the provider shortage and democratize access to healthcare, particularly for vulnerable communities. The company has raised over $100 million as of January 2026, backed by investors such as Oak HC/FT and Y Combinator. Akido Labs was also named a Fierce 15 honoree in 2026.

Why it Matters

Rothstein's experience at Final, Inc., where he co-founded the product that became the Apple Card, has taught him the importance of building for the actual human moment. This lesson is particularly relevant in healthcare, where solutions must be tailored to the needs of patients, especially those in underserved communities.

“Most AI healthcare companies sell software to hospital systems and hope something changes,” Rothstein explained. “Akido owns the clinical network where the software and AI actually run. That closed loop is what makes rapid iteration and true innovation possible.”

In 2022, Akido Labs launched Akido Care, a network that includes nearly 100 clinics offering primary and specialty care. The network comprises more than 240 providers across 26 specialties, serving over 500,000 patients. By owning the clinical network, Akido can ensure that its AI solutions are integrated seamlessly into patient care, leading to better outcomes and a more personalized experience.

The company's approach is supported by the ACCESS model, which reimburses disease management applications for Medicare beneficiaries with or without human supervision as long as patients achieve clinical improvements. This model aligns financial incentives with patient outcomes, further enhancing Akido's ability to deliver high-quality care.

The Bottom Line

Akido Labs' AI-native platform and integrated clinical network represent a significant shift in how healthcare is delivered and accessed. By focusing on the actual human moment and leveraging technology to improve patient experiences, Rothstein and his team are addressing critical issues in the healthcare system. With strong financial backing and a clear mission, Akido Labs is well-positioned to make a meaningful impact on healthcare delivery, particularly for vulnerable communities.

The company's success will depend on its ability to continue innovating and scaling its solutions while maintaining a patient-centric approach. As the healthcare landscape evolves, Akido Labs' model could serve as a blueprint for other organizations looking to leverage AI and technology to improve care access and outcomes.